S2 Genomics is a biotechnology company specializing in the development of laboratory automation solutions for processing solid tissues for single-cell applications. The company, founded in 2016 by Dr. Stevan Jovanovich, is headquartered in Livermore, California. S2 Genomics focuses on automated processing systems that convert tissue samples into single-cell or nuclei preparations, which are crucial for genomics and cell biology studies. The company has raised $16 million in Series A funding, led by BroadOak Capital Partners and RCT.
| Attribute | Information |
|---|---|
| Founding Date | 2016 |
| Headquarters | Livermore, CA, USA |
| Founders | Dr. Stevan Jovanovich |
| Revenue | $945,000 (2024) |
| Key Investors | BroadOak Capital Partners, RCT |
| Industry | Biotechnology, Genomics |
| Number of Employees | 31 |
S2 Genomics was founded in 2016 by Dr. Stevan Jovanovich with a mission to innovate in automated tissue processing for single-cell analysis. The company's initial focus was on developing the Singulator, an instrument designed to ease sample preparation for single-cell genomics. By automating the complex and labor-intensive process of tissue dissociation, S2 Genomics aimed to improve the efficiency and accuracy of cell biology studies. The company quickly gained attention for its potential to streamline workflows in genomics laboratories, securing early partnerships with research institutions and biotech firms.
S2 Genomics operates in the space between traditional laboratory processes and cutting-edge genomic technologies. The company’s flagship product, the Singulator, facilitates the preparation of single-cell or nuclei suspensions from solid tissue samples. The machine's ability to handle various types of tissue, including fresh, frozen, and FFPE, while maintaining high yield and viability, has led to its adoption in leading research labs and institutions. Notable milestones include:
Currently, S2 Genomics is positioned as a leader in single-cell preparation technologies. The company’s products are widely used in academic research, pharmaceutical development, and clinical settings, particularly for cancer research, due to their ability to reliably dissociate complex tissue structures into analyzable cellular components. As the demand for single-cell analysis grows, S2 Genomics is expected to expand its market share through continued innovation and strategic partnerships.
S2 Genomics is a pioneering entity in the biotechnology sector, providing essential tools for the burgeoning field of single-cell analysis. With a solid foundation in automation and a commitment to advancing genomic research, the company's trajectory is poised for growth in tandem with the expanding genomics market. Their focus on innovation and strategic expansion suggests a promising future that could significantly impact the research methodologies and applications in biotechnology and healthcare industries.